Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label study of PNEUMOVAX 23 in Russian subjects at risk for pneumococcal disease
2015-001656-29Phase 3
- Sponsor
- Merck & Co.
- Start
- Apr 2015
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of 23-valent pneumococcal polysaccharide vaccine in pneumococcal disease, sponsored by Merck & Co. Primary endpoints: Primary immunogenicity endpoints and Safety and tolerability.
02
Drugs
23-valent pneumococcal polysaccharide vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2015-001656-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001656-29.